Patients with chronic cystitis were diagnosed by urine cytology and diagnostic cystoscopy coupled with histopathological examination. There were no signs of premalignant lesions (squamous metaplasia, dysplastic changes, or leukoplakia) nor were signs of prostatic enlargement found. Selleckchem URMC-099 Under the same diagnostic protocols done for bladder cancer patients, the chronic cystitis patients were grouped into 16 schistosomal cystitis (SC) patients and 28 non-schistosomal cystitis (NSC) patients. Control group Twenty age- and sex- matched individuals (12 men and 8 women) at mean age 58.3 ± 6.1 years old were involved from the Middle East
region. Their bladders were investigated by routine cystoscopy and biopsies were taken. They were found free of bladder cancer or any other bladder disease or inflammation, therefore, they were considered as control group (CTL). Processing of biopsies The bladder cancer patients, the chronic cystitis patients, and CTL subjects underwent transurethral resection of bladder tumor (TUR-BT), cystitis tissues, and normal mucosal tissues respectively. The retrieved
specimens were composed of multiple pieces, 2–5 mm in thickness. Specimens were immersed in 10% formalin in order to make a paraffin block. The histopathological NSC 683864 paraffin blocks of biopsies were sectioned into 4 um thick sections. Hematoxylin and Eosin slides were prepared and examined by a histopathologist for confirming the histopathological diagnosis, the grade, and the invasiveness
of the tumor. A set of steps were pursued under the supervision of a pathologist to minimize as could as possible the fixation-related loss of target proteins. These steps were: minimal prefixation time of 1 hour, the use of cold 4% paraformaldehyde and cold fixation at 4°C, and short duration of fixation up to 5 hours [18]. Moreover, the paraffin-embedded sections processed for immunohistochemistry (IHC) assay were examined in a period not more than 3 days. It was stated that insignificant loss of nucleic acids or proteins was observed within the first 3 days of fixation-paraffin GSK458 price embedding [18]. Immunohistochemistry assay Antibodies IHC staining was conducted using a set of mouse monoclonal antibodies; anti-p53, anti-p16, anti bcl-2, and anti-c-myc Pazopanib in vitro (InnoGenex, USA) and anti Ki-67, anti-Rb-1, and anti-EGFR (DakoCytomation). Secondary biotinylated goat anti-mouse antibodies were used (DakoCytomation). Antibodies were diluted in the recommended antibody diluting buffer (Dako). The working dilutions and the final concentrations of the primary antibodies were 1:100 and 0.005 mg/mL for anti-p53, 1:120 and 0.008 mg/mL for anti-p16, 1:75 and 0.006 mg/mL for anti-bcl-2, 1:100 and 0.01 mg/mL for c-myc, 1: 50 and 0.01 mg/mL for anti-Rb-1, 1:200 and 0.005 mg/mL for anti-ki67, and 1:120 and 0.008 mg/mL for anti-EGFR antibodies. The used dilution and concentration of the biotinylated goat anti-mouse antibodies were 1:800 at final concentration 0.0025 mg/mL.